Cellectar Biosciences (NASDAQ: CLRB) and Aceto (NASDAQ:ACET) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Volatility and Risk

Cellectar Biosciences has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Aceto has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Cellectar Biosciences and Aceto, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences 0 0 0 0 N/A
Aceto 0 2 1 0 2.33

Aceto has a consensus target price of $15.00, suggesting a potential upside of 32.39%. Given Aceto’s higher probable upside, analysts plainly believe Aceto is more favorable than Cellectar Biosciences.

Earnings & Valuation

This table compares Cellectar Biosciences and Aceto’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellectar Biosciences N/A N/A -$6.18 million ($1.07) -1.12
Aceto $638.32 million 0.53 $11.37 million $0.21 53.95

Aceto has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Aceto, indicating that it is currently the more affordable of the two stocks.

Dividends

Aceto pays an annual dividend of $0.26 per share and has a dividend yield of 2.3%. Cellectar Biosciences does not pay a dividend. Aceto pays out 123.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Insider and Institutional Ownership

1.7% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 80.8% of Aceto shares are held by institutional investors. 10.2% of Cellectar Biosciences shares are held by company insiders. Comparatively, 4.1% of Aceto shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cellectar Biosciences and Aceto’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectar Biosciences N/A -108.18% -91.41%
Aceto 1.07% 10.18% 3.95%

Summary

Aceto beats Cellectar Biosciences on 12 of the 14 factors compared between the two stocks.

About Cellectar Biosciences

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

About Aceto

Aceto Corporation (Aceto) is engaged in the marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products. The Company’s business is organized along product lines into three segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. As of June 30, 2016, it distributed over 1,100 chemical compounds used primarily as finished products or raw materials in the agricultural, coatings and industrial chemical industries. The Human Health segment includes finished dosage form generic drugs and nutraceutical products. As of June 30, 2016, the Pharmaceutical Ingredients segment had two product groups: Active Pharmaceutical Ingredients and Pharmaceutical Intermediates. The Performance Chemicals segment includes specialty chemicals and agricultural protection products.

Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.